Strattec vs. Dorman Products: Which Stock is a Better Buy Right Now?

Strattec Security (STRT) emerges as a preferred investment over Dorman Products (DORM) for auto parts exposure, despite both companies' recent stock performance. While STRT's shares have surged 145.1% year-over-year compared to DORM's 37.7%, the analysis emphasizes STRT's superior fundamentals: over 90% of its U.S. sales are tariff-free, with only 6% of total sales affected by recent tariffs, significantly de-risking its supply chain compared to DORM's 30-40% reliance on Chinese sourcing. Additionally, STRT maintains a robust balance sheet with a low 5.25% debt-to-capitalization, offering greater financial flexibility, and trades at a more favorable 5.15x EV/EBITDA multiple versus DORM's 10.43x, positioning it as a 'Strong Buy' due to its resilience and valuation.

Analysis

A comparative analysis of auto parts manufacturers Strattec Security (STRT) and Dorman Products (DORM) reveals significant fundamental divergences despite strong share price performance from both over the past year (STRT +145.1%, DORM +37.7%). STRT demonstrates superior resilience to geopolitical trade risks, with over 90% of its U.S. sales qualifying for tariff-free treatment and only 6% of total sales expected to be affected by recent tariffs. This contrasts sharply with DORM's considerable exposure, as it sources 30% to 40% of its products from China, creating vulnerability to tariff shocks and supply chain disruptions. Financially, STRT possesses a much stronger balance sheet, evidenced by a debt-to-capitalization ratio of just 5.25% versus the industry composite of 27.8%, affording it greater flexibility for organic growth initiatives. While DORM's free cash flow is healthy, its allocation toward debt repayment and shareholder returns may limit its agility. Furthermore, STRT trades at a compelling valuation discount, with a trailing EV/EBITDA multiple of 5.15x, less than half of DORM's 10.43x, positioning it as a fundamentally more attractive and less-risky investment.

Key Decisions for Investors

• Investors should consider STRT a more favorable investment than DORM, given its insulation from tariff impacts, superior balance sheet health, and significantly more attractive valuation multiple.
• For those holding or evaluating DORM, it is critical to monitor for any escalation in U.S.-China trade tensions, as the company's 30-40% sourcing from China represents a material risk to its cost structure and operational stability.
• The significant discount in STRT's EV/EBITDA multiple (5.15x vs. DORM's 10.43x) suggests a potential long opportunity, as the market may not have fully priced in its fundamental strengths and defensive characteristics relative to peers.